Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

Over the past 4 decades, basic research has provided crucial information regarding the
cellular and molecular biology of cancer. In particular, the relevance of cancer …

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but
little is known about the putative mechanisms by which the BM microenvironment plays an …

Multiple myeloma (MM) is characterized by the impaired osteogenic differentiation of
mesenchymal stromal cells (MSCs). However, the underlying molecular mechanisms are …

Accumulating evidence suggests that mesenchymal stem cells (MSCs) are recruited to the
tumor microenvironment; however, controversy exists regarding their role in solid tumors. In …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-
associated inflammation impacts normal niches for haematopoietic progenitor cells and …

Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …

The development and effectiveness of novel therapies in multiple myeloma have been
established in large clinical trials. However, multiple myeloma remains an incurable …

Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a
complex interactive network of tumour cells and the bone marrow (BM) stromal …